Neuroprotective Effects of a Novel Inhibitor of c-Jun N-Terminal Kinase in the Rat Model of Transient Focal Cerebral Ischemia; Cells; Vol. 9, iss. 8

Podrobná bibliografie
Parent link:Cells
Vol. 9, iss. 8.— 2020.— [1860, 12 p.]
Korporativní autor: Национальный исследовательский Томский политехнический университет Инженерная школа новых производственных технологий Научно-образовательный центр Н. М. Кижнера
Další autoři: Plotnikov M. B. Mark Borisovich, Chernysheva G. A. Galina Anatoljevna, Smolyakova V. A. Veronika Alekseevna, Aliev O. I. Oleg Ibragimovich, Trofimova E. S. Evgeniya Sergeevna, Sherstoboev E. Yu. Egeny Yurjevich, Osipenko A. N. Anton Nikolaevich, Khlebnikov A. I. Andrey Ivanovich, Anfinogenova Ya. J. Yana Jonovna, Schepetkin (Shchepyotkin) I. A. Igor Aleksandrovich, Atochin D. N. Dmitry Nikolaevich
Shrnutí:Title screen
A novel specific inhibitor of c-Jun N-terminal kinase, 11H-indeno[1,2-b]quinoxalin-11-one oxime sodium salt (IQ-1S), has a high affinity to JNK3 compared to JNK1/JNK2. The aim of this work was to study the mechanisms of neuroprotective activity of IQ-1S in the models of reversible focal cerebral ischemia (FCI) in Wistar rats. The animals were administered with an intraperitoneal injection of IQ-1S (5 and 25 mg/kg) or citicoline (500 mg/kg). Administration of IQ-1S exerted a pronounced dose-dependent neuroprotective effect, not inferior to the effects of citicoline. Administration of IQ-1S at doses of 5 and 25 mg/kg reduced the infarct size by 20% and 50%, respectively, 48 h after FCI, whereas administration of citicoline reduced the infarct size by 34%. The administration of IQ-1S was associated with a faster amelioration of neurological status. Control rats showed a 2.0-fold increase in phospho-c-Jun levels in the hippocampus compared to the corresponding values in sham-operated rats 4 h after FCI. Administration of IQ-1S at a dose of 25 mg/kg reduced JNK-dependent phosphorylation of c-Jun by 20%. Our findings suggest that IQ-1S inhibits JNK enzymatic activity in the hippocampus and protects against stroke injury when administered in the therapeutic and prophylactic regimen in the rat model of FCI.
Jazyk:angličtina
Vydáno: 2020
Témata:
On-line přístup:https://doi.org/10.3390/cells9081860
Médium: Elektronický zdroj Kapitola
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=663489